Novel approaches to treating leptomeningeal metastases

Journal of Neuro-Oncology

Volumn 106, Issue 2, 2012, Pages 225-234

  Grewal, Jai ^a   Saria, Marlon Garzo ^b,c   Kesari, Santosh ^b,c  

^a NSPC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Biomarkers; Brain metastases; Cerebrospinal fluid; Leptomeningeal metastases; Leptomeninges; Lymphomatous meningitis

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CHEMOKINE RECEPTOR CXCR4; CYTARABINE; ERLOTINIB; GEFITINIB; IRINOTECAN; LAPATINIB; METHOTREXATE; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; TEMOZOLOMIDE; TRASTUZUMAB; VASCULOTROPIN;

BRAIN METASTASIS; BRAIN VENTRICLE PERITONEUM SHUNT; BREAST CANCER; CANCER PALLIATIVE THERAPY; COLORECTAL CANCER; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; GLIOBLASTOMA; HUMAN; HYDROCEPHALUS; KIDNEY CANCER; LARGE CELL LYMPHOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MENINGEAL METASTASIS; MENINGITIS; NEUROPROTECTION; NONHODGKIN LYMPHOMA; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; QUALITY OF LIFE; REVIEW; SOLID TUMOR; TREATMENT OUTCOME;

HUMANS; MENINGEAL CARCINOMATOSIS; NEOPLASM METASTASIS;

EID: 82955162455     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-011-0686-2     Document Type: Review

References (85)

1. S Kesari TT Batchelor 2003 Leptomeningeal metastases Neurol Clin N Am 21 25 66 (Pubitemid 36169344)
2. B Gleissner MC Chamberlain 2006 Neoplastic meningitis Lancet Neurol 5 443 452 16632315 10.1016/S1474-4422(06)70443-4
3. MD Groves KR Hess VK Puduvalli, et al. 2009 Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma J Neurooncol 4 229 234 10.1007/s11060-009-9819-2
4. MS Mitchell 1989 Relapse in the central nervous system in melanoma patients successfully treated with biomodulators J Clin Oncol 7 1701 1709 2809683 1:STN:280:DyaK3c%2FjvFCmsA%3D%3D (Pubitemid 19272842)
5. WP O'Meara SA Borkar HE Stambuk, et al. 2007 Leptomeningeal metastasis Curr Probl Cancer 31 372 424 10.1016/j.currproblcancer.2007.07.001 (Pubitemid 350119844)
6. WH Theodore S Gendelman 1981 Meningeal carcinomatosis Arch Neurol 38 696 699 6975612 10.1001/archneur.1981.00510110056008 1:STN:280: DyaL38%2FmslCjsQ%3D%3D (Pubitemid 11029559)
7. HY Yap BS Yap S Rasmussen, et al. 1982 Treatment for meningeal carcinomatosis in breast cancer Cancer 50 219 222 6177395 10.1002/1097- 0142(19820715)50:2<219::AID-CNCR2820500209>3.0.CO;2-7 1:STN:280: DyaL383gvVWltA%3D%3D (Pubitemid 12089377)
8. M Jorda P Ganjei-Azar M Nadji 1998 Cytologic characteristics of meningeal carcinomatosis. Increased diagnostic accuracy using carcinoembryonic antigen and epithelial membrane antigen immunocytochemistry Arch Neurol 55 181 184 9482359 10.1001/archneur.55.2.181 1:STN:280:DyaK1c7ktFClsQ%3D%3D (Pubitemid 28110060)
9. Chamberlain MC (2006) CSF Disseminated primary brain tumors. In: Newton HB (ed) Handbook of brain tumor chemotherapy. Elsevier Science, San Diego, pp 316-326
10. IT Gavrilovic JB Posner 2005 Brain metastases: epidemiology and pathophysiology J Neurooncol 75 5 14 16215811 10.1007/s11060-004-8093-6 (Pubitemid 41548673)
11. JP Glass M Melamed NL Chernik, et al. 1979 Malignant cells in cerebrospinal fluid (CSF): the meaning of a positive CSF cytology Neurology 29 1369 1375 573381 1:STN:280:DyaL3c%2FhtF2ktQ%3D%3D (Pubitemid 9256272)
12. B Gleissner MC Chamberlain 2007 Treatment of CNS dissemination in systemic lymphoma J Neurooncol 84 107 117 17332946 10.1007/s11060-007-9353-z 1:STN:280:DC%2BD2szpslChsQ%3D%3D (Pubitemid 47103452)
13. C Hatton 2005 Lymphomatous meningitis Haematologica Rep 1 108 109
14. MC Chamberlain 2008 Neoplastic meningitis Curr Neurol Neurosci Rep 8 249 258 18541120 10.1007/s11910-008-0038-6
15. S Yoshida K Morii M Watanabe, et al. 2000 Characteristic features of malignant lymphoma with central nervous system involvement Surg Neurol 53 163 167 10713195 10.1016/S0090-3019(99)00186-X 1:STN:280:DC%2BD3c7os1Glsg%3D%3D (Pubitemid 30122323)
16. MJ Glantz BF Cole LK Glantz, et al. 1998 Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results Cancer 82 733 739 9477107 10.1002/(SICI)1097-0142(19980215)82:4<733::AID-CNCR17>3.0.CO;2-Z 1:STN:280:DyaK1c7jsF2ktg%3D%3D (Pubitemid 28090286)
17. MS Ward 1999 The use of flow cytometry in the diagnosis and monitoring of malignant hematological disorders Pathology 31 382 392 10643011 10.1080/003130299104774 1:STN:280:DC%2BD3c7gslKhsQ%3D%3D (Pubitemid 30009101)
18. CE Johanson JA Duncan EG Stopa, et al. 2005 Enhanced prospects for drug delivery and brain targeting by the choroid plexus-CSF route Pharm Res 22 1011 1037 16028003 10.1007/s11095-005-6039-0 1:CAS:528:DC%2BD2MXmt1ynur0%3D (Pubitemid 41130789)
19. Z Kobayashi K Tsuchiya A Machida, et al. 2009 Metastatic CNS lymphoma presenting with periventricular dissemination-MRI and neuropathological finding in an autopsy case J Neurological Sci 277 109 113 10.1016/j.jns.2008.10.029
20. S Levine 1987 Choroid plexus: target for systemic disease and pathway to the brain Lab Invest 56 231 233 2950275 1:STN:280:DyaL2s7kt1OhtQ%3D%3D (Pubitemid 17065342)
21. MB Oldstone PJ Southern 1993 Trafficking of activated cytotoxic T lymphocytes into the central nervous system: use of a transgenic model J Neuroimmunol 46 25 31 8360331 10.1016/0165-5728(93)90230-V 1:STN:280: DyaK3szmslSgug%3D%3D
22. MD Groves 2003 The pathogenesis of neoplastic meningitis Curr Oncol Rep 5 15 23 12493146 10.1007/s11912-003-0082-y (Pubitemid 38898762)
23. C Alix-Panabieres S Riethdorf K Pantel 2008 Circulating tumor cells and bone marrow micrometastasis Clin Cancer Res 14 5013 5021 18698019 10.1158/1078-0432.CCR-07-5125 1:CAS:528:DC%2BD1cXpslKgtr4%3D
24. M Kakarala MS Wicha 2008 Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy J Clin Oncol 26 2813 2820 18539959 10.1200/JCO.2008.16.3931
25. X Li MT Lewis J Huang, et al. 2008 Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy J Natl Cancer Inst 100 672 679 18445819 10.1093/jnci/djn123 1:CAS:528:DC%2BD1cXlslymtbg%3D
26. Fidler IJ, Langley RR, Kerbel RS et al (2005) Angiogenesis. In: De Vita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice in oncology. Lippincott Williams & Wilkins, New York, pp 129-135
27. A Kraft K Weindel A Ochs, et al. 1999 Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease Cancer 85 178 187 9921991 10.1002/(SICI)1097-0142(19990101)85:1<178::AID- CNCR25>3.0.CO;2-7 1:STN:280:DyaK1M7hvV2ltg%3D%3D (Pubitemid 29031373)
28. G Stockhammer W Poewe S Burgstaller, et al. 2000 Vascular endothelial growth factor in CSF: a biological marker for carcinomatous meningitis Neurology 54 1670 1676 10762512 1:CAS:528:DC%2BD3cXjtF2ltL0%3D
29. S Goswami U Phillippar D Sun, et al. 2009 Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo Clin Exp Metastasis 26 153 159 18985426 10.1007/s10585-008-9225-8 1:CAS:528:DC%2BD1MXhvVKqtbk%3D
30. C Kadoch P Treseler JL Rubenstein 2006 Molecular pathogenesis of primary central nervous system lymphoma Neurosurg Focus 21 E1 17134111 10.3171/foc.2006.21.5.2
31. B-C Lee T-H Lee S Avraham, et al. 2004 Involvement of the chemokine receptor CXCR4 and its ligand stromal cell-derived factor 1α in breast cancer cell migration through human brain microvascular endothelial cells Mol Cancer Res 2 327 338 15235108 1:CAS:528:DC%2BD2cXltlOrurw%3D (Pubitemid 39025295)
32. S Singh KC Nannuru A Sandanandam, et al. 2009 CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion Br J Cancer 100 1638 1646 19401689 10.1038/sj.bjc.6605055 1:CAS:528:DC%2BD1MXlslCht7g%3D
33. U Philippar ET Roussos M Oser, et al. 2008 A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis Dev Cell 15 813 828 19081071 10.1016/j.devcel.2008.09.003 1:CAS:528:DC%2BD1cXhsFWgsbjO
34. J Wyckoff W Wang EY Lin, et al. 2004 A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors Cancer Res 64 7022 7029 15466195 10.1158/0008-5472.CAN-04-1449 1:CAS:528: DC%2BD2cXotFalsLg%3D (Pubitemid 39331012)
35. RJ Van Oostenbrugge AHN Hopman FCS Ramaekers, et al. 1998 In situ hybridization: a possible diagnostic aid in leptomeningeal metastasis J Neurooncol 38 127 133 9696362 10.1023/A:1005926624303 (Pubitemid 28306198)
36. RJ Van Oostenbrugge AHN Hopman JW Arends, et al. 2000 Treatment of leptomeningeal metastasis evaluated by interphase cytogenetics J Clin Oncol 18 2053 2058 10811670 (Pubitemid 30324358)
37. JM Baehring FH Hochberg RA Betensky, et al. 2006 Immunoglobulin gene rearrangement analysis in cerebrospinal fluid of patients with lymphoproliferative processes J Neurol Sci 247 208 216 16764890 10.1016/j.jns.2006.05.044 1:CAS:528:DC%2BD28XpsVKksrg%3D (Pubitemid 44339543)
38. B Gleissner J Siehl A Korfel, et al. 2002 CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes Neurology 58 390 396 11839837 1:STN:280:DC%2BD387ktVOmug%3D%3D (Pubitemid 34150912)
39. SL Berg MC Chamberlain 2003 Systemic chemotherapy, intrathecal chemotherapy, and symptom management in the treatment of leptomeningeal metastasis Curr Oncol Rep 5 29 40 12493148 10.1007/s11912-003-0084-9 (Pubitemid 38898764)
40. SL Berg MC Chamberlain 2005 Current treatment of leptomeningeal metastases: systemic chemotherapy, intrathecal chemotherapy and symptom management Cancer Treat Res 125 121 146 16211887 10.1007/0-387-24199-X-8
41. MC Chamberlain C Nolan LE Abrey 2005 Leukemic and lymphomatous meningitis: incidence, prognosis and treatment J Neurooncol 75 71 83 16215818 10.1007/s11060-004-8100-y (Pubitemid 41548680)
42. MC Chamberlain PA Kormanik D Barba 1997 Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases J Neurosurg 87 694 699 9347977 10.3171/jns.1997.87.5.0694 1:STN:280: DyaK1c%2Fgs1ajsg%3D%3D (Pubitemid 27454587)
43. T Siegal A Lossos MR Pfeffer 1994 Leptomeningeal metastases: analysis of 31 patients with sustained off-therapy response following combined-modality therapy Neurology 44 1463 1469 8058150 1:STN:280:DyaK2czjs1Shsg%3D%3D
44. MJ Glantz WA Hall BF Cole, et al. 1995 Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status Cancer 75 2919 2931 7773943 10.1002/1097-0142(19950615)75: 12<2919::AID-CNCR2820751220>3.0.CO;2-9 1:STN:280:DyaK2M3pt1altQ%3D%3D
45. MJ Glantz WA Hall BF Cole, et al. 1995 Diagnosis, management, and survival of patients with leptomeningeal cancer based on cerebrospinal fluid-flow status Cancer 75 12 2919 2931 7773943 10.1002/1097-0142(19950615)75: 12<2919::AID-CNCR2820751220>3.0.CO;2-9 1:STN:280:DyaK2M3pt1altQ%3D%3D
46. MC Chamberlain M Glantz 2006 Ventriculoperitoneal shunt in patients with leptomeningeal metastases Neurology 66 783 16534138 10.1212/01.wnl.0000205135. 85388.01
47. AM Omuro EC Lallana MH Bilsky, et al. 2005 Ventriculoperitoneal shunt in patients with leptomeningeal metastases Neurology 10 1625 1627 10.1212/01.WNL.0000160396.69050.DC (Pubitemid 40617704)
48. J Mocco MI Tomey RJ Komotar, et al. 2006 Ventriculoperitoneal shunting of idiopathic normal pressure hydrocephalus increases midbrain size: a potential mechanism for gait improvement Neurosurgery 59 847 851 17038948 10.1227/01.NEU.0000232655.78335.D5 1:STN:280:DC%2BD28ngs1Kitw%3D%3D
49. D Schiff C Kline H Meltzer, et al. 2009 Palliative venticuloperitoneal shunt in a pediatric patient with recurrent metastatic medulloblastoma J Palliat Med 12 391 393 19327082 10.1089/jpm.2008.0227
50. J Lokich H Levine I Nasser 1998 Malignancy-related hydrocephalus: clinical features and results of ventricular peritoneal shunt procedure in three patients Am J Clin Oncol 21 366 368 9708635 10.1097/00000421-199808000-00010 1:STN:280:DyaK1cznt1ensg%3D%3D (Pubitemid 28366905)
51. Y Eralp P Saip Z Aydin, et al. 2008 Leptomeningeal dissemination of ovarian carcinoma through a ventriculoperitoneal shunt Gynecol Oncol 108 248 250 17961641 10.1016/j.ygyno.2007.09.024 (Pubitemid 350299447)
52. M Matsumae O Sato K Itoh, et al. 1989 Quantification of cerebrospinal fluid shunt flow rates. Assessment of the programmable pressure valve Childs Nerv Syst 5 356 360 2611769 10.1007/BF00271892 1:STN:280:DyaK3c7isVeltw%3D%3D (Pubitemid 20072144)
53. M Chiafery 2006 Care and management of the child with shunted hydrocephalus Pediatr Nurs 32 222 225 16802679
54. MJ Glantz S LaFollette KA Jaeckle, et al. 1999 Randomized trial of a slow-release versus standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis J Clin Oncol 17 3110 3116 10506606 1:CAS:528:DyaK1MXmslGmtL8%3D (Pubitemid 29470639)
55. JA Garcia-Marco C Panizo ES Garcia, et al. 2009 Efficacy and safely of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma Cancer 115 1892 1898 19235254 10.1002/cncr.24204 1:CAS:528:DC%2BD1MXlt1ygu70%3D
56. GP Adams LM Weiner 2005 Monoclonal antibody therapy of cancer Nat Biotechnol 23 1147 1157 16151408 10.1038/nbt1137 1:CAS:528:DC%2BD2MXpvVyrtr0%3D (Pubitemid 41486396)
57. DA Cameron S Stein 2008 Drug insight: intracellular inhibitors of HER2-clinical development of lapatinib in breast cancer Nat Clin Pract Oncol 5 512 520 18594499 10.1038/ncponc1156 1:CAS:528:DC%2BD1cXhtVGgt7fI
58. NU Lin V Diéras D Paul, et al. 2009 Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer Clin Cancer Res 15 1452 1459 19228746 10.1158/1078-0432.CCR-08-1080 1:CAS:528:DC%2BD1MXitVOktLo%3D
59. Onishi H, Morisaki T, Nakafusa Y et al. (2011) Objective response with lapatinib in patients with meningitis carcinomatosa derived from HER2/HER1-negative breast cancer. Int J Clin Oncol. doi: 10.1007/s10147-011- 0195-5
60. TJ Lynch DW Bell R Sordella, et al. 2004 Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2129 2139 15118073 10.1056/NEJMoa040938 1:CAS:528:DC%2BD2cXktF2js7c%3D (Pubitemid 38637993)
61. JG Paez PA Janne JC Lee, et al. 2004 EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 1497 1500 15118125 10.1126/science.1099314 1:CAS:528:DC%2BD2cXksVGmsbs%3D (Pubitemid 38720929)
62. A Inoue K Kobayashi K Usui, et al. 2009 First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 27 1394 1400 19224850 10.1200/JCO.2008.18.7658 1:CAS:528:DC%2BD1MXksF2iu7c%3D
63. AM Omuro MG Kris VA Miller, et al. 2005 High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib Cancer 103 2344 2348 15844174 10.1002/cncr.21033 1:CAS:528:DC%2BD2MXlsFSntL4%3D (Pubitemid 40686581)
64. Jackman DM, Kesari S, Cioffredi L et al. (2009) Phase I study of high dose gefitinib in patients with leptomeningeal metastases from EGFR-mutant non-small cell lung cancer. Presented at the 13th World Congress on Lung Cancer San Francisco, 31st July-4th August 2009; Poster P1.189
65. HG Yi HJ Kim YJ Kim, et al. 2009 Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI Lung Cancer 65 80 84 19059670 10.1016/j.lungcan.2008.10.016
66. DM Jackman A Holmes N Lindeman, et al. 2006 Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib J Clin Oncol 24 4517 4520 16983123 10.1200/JCO.2006.06.6126 (Pubitemid 46630993)
67. JL Clarke W Pao N Wu, et al. 2010 High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer J Neurooncol 99 2 283 286 20146086 10.1007/s11060-010-0128-6
68. Tetsumoto S, Osa A, Kijima T et al (2011) Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib. Int J Clin Oncol. doi: 10.1007/s10147-011-0256-9
69. T Shigekawa H Takeuchi M Misumi, et al. 2009 Successful treatment of leptomeningeal metastases from breast cancer using the combination of trastuzumab and capecitabine: a case report Breast Cancer 16 88 92 18478315 10.1007/s12282-008-0056-x
70. M Ekenel AM Hormigo S Peak, et al. 2007 Capecitabine therapy of central nervous system metastases from breast cancer J Neurooncol 85 223 227 17611719 10.1007/s11060-007-9409-0 1:CAS:528:DC%2BD2sXhtl2gs7rI (Pubitemid 47629405)
71. YL Tham L Hinckley BS Teh, et al. 2006 Long-term clinical response in leptomeningeal metastases from breast cancer treated with capecitabine monotherapy: a case report Clin Breast Cancer 7 164 166 16800978 10.3816/CBC.2006.n.028 (Pubitemid 44044015)
72. S Paydas K Bicakci S Yavuz 2009 Dramatic response with capecitabine after cranial radiation to the brain parenchymal and leptomeningeal metastases from lung cancer Eur J Intern Med 20 96 99 19237101 10.1016/j.ejim.2008.04.015 1:CAS:528:DC%2BD1MXit1Sgurk%3D
73. E Rivera C Meyers M Groves, et al. 2006 Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma Cancer 107 1348 1354 16909414 10.1002/cncr.22127 1:CAS:528:DC%2BD28XhtVOns73K (Pubitemid 44452785)
74. IJ Fidler S Yano RD Zhang, et al. 2002 The seed and soil hypothesis: vascularization and brain metastases Lancet Oncol 3 53 57 11905606 10.1016/S1470-2045(01)00622-2 1:CAS:528:DC%2BD38Xhtleitb0%3D (Pubitemid 34121146)
75. A Bhaskara C Eng 2008 Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases Clin Colorectal Cancer 7 65 68 18279580 10.3816/CCC.2008.n.010 1:CAS:528:DC%2BD1cXislGis78%3D (Pubitemid 351252454)
76. LS Kim S Huang W Lu, et al. 2004 Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice Clin Exp Metastasis 21 107 118 15168728 10.1023/B:CLIN.0000024761.00373.55 1:CAS:528:DC%2BD2cXjt1Clu7s%3D (Pubitemid 38988084)
77. JB Posner 1996 Brain metastases: 1995 a brief review J Neurooncol 27 287 293 8847563 10.1007/BF00165486 1:STN:280:DyaK283mslCmtA%3D%3D (Pubitemid 26098128)
78. GY Ku G Krol DH Ilson 2007 Successful treatment of leptomeningeal disease in colorectal cancer with a regimen of bevacizumab, temozolomide, and irinotecan J Clin Oncol 25 e14 e16 17470852 10.1200/JCO.2006.10.3317
79. RS Cvetkovic CM Perry 2006 Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukemia Drugs 66 791 820 16706552 10.2165/00003495-200666060-00005 1:CAS:528:DC%2BD28XlvF2jsLw%3D (Pubitemid 43778729)
80. R Marcus A Hagenbeek 2007 The therapeutic use of rituximab in non-Hodgkin's lymphoma Eur J Haematol Suppl 67 5 14 17206982 10.1111/j.1600-0609.2006.00789.x 1:CAS:528:DC%2BD2sXitlCgt7k%3D (Pubitemid 44934857)
81. JL Rubenstein J Fridlyand L Abrey, et al. 2007 Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma J Clin Oncol 25 1350 1355 17312328 10.1200/JCO.2006.09.7311 1:CAS:528:DC%2BD2sXlt1Ghurw%3D (Pubitemid 46706881)
82. MC Chamberlain SK Johnston A Van Horn, et al. 2009 Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C J Neurooncol 91 271 277 18820836 10.1007/s11060-008-9707-1 1:CAS:528:DC%2BD1MXjvFelsw%3D%3D
83. SH Bernstein JM Unger M Leblanc, et al. 2009 Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516-the southwest oncology group J Clin Oncol 27 114 119 19047289 10.1200/JCO.2008.16.8021
84. Canales M, Peñarrubia MJ, Salar A et al. (2008) Efficacy and safety of intrathecal liposomal cytarabine injection given prophylactically in patients with high-risk diffuse large B-cell lymphoma: a report of 24 patients in Spain. Abstract Presented at: the 13th Congress of the European Hematology Association, Copenhagen, Denmark, 12-15 June
85. HY Lim E Thiel MJ Glantz 2008 To protect and defend: central nervous system prophylaxis in patients with non-Hodkin's lymphoma Curr Opin Oncol 20 495 501 19106650 10.1097/CCO.0b013e32830b829e